Sector:HealthcareAll sectors

Last updated1 minute ago

LLY·Eli Lilly and Company

(%)

Overnight (%)

High

$1,264.73

Open

$1,249.00

Market Cap

1153.16B

52W High

$1,292.65

Low

$1,229.62

P. Close

$1,233.57

P/E

43.17

52W Low

$694.23

Fwd P/E

26.25

DailyIQ Est.

$1384.99

Inst. Ownership

0.5%

Short Interest

0.99%

Technical Score (1D)

BUY

News Sentiment

BULLISH

Eli Lilly’s shares surged after the company announced a 6.4 % lift in revenue from its flagship obesity and diabetes drugs Mounjaro and Zepbound, prompting a higher full‑year guidance. The same day the UK regulator cleared Foundayo, an oral GLP‑1 pill, expanding Lilly’s weight‑management and diabetes portfolio and reinforcing its leadership in the GLP‑1 space. These developments signal that Lilly’s core therapeutic area is gaining traction, but payer and regulatory uncertainties still loom as potential demand dampeners. Earlier this week, a new weight‑loss candidate showed promising early‑trial efficacy, positioning Lilly to capture a larger share of the rapidly expanding obesity market and diversifying beyond its traditional diabetes focus. The company’s earnings beat expectations, and technical analysis points to a bullish breakout, suggesting short‑term upside momentum. While no official plan has been announced, speculation that Lilly could consider a stock split after nearly three decades of no split could add a layer of investor excitement and affect trading dynamics. In the next 1–10 trading days, watch for the UK’s final approval of Foundayo, any updates on the new weight‑loss drug’s regulatory status, and the company’s guidance revisions. Also monitor for any signals from Lilly’s management about a potential stock split, as that could influence short‑term liquidity and investor sentiment.

LLY|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NYQ

Country

United States

Website

lilly.com

Symbol

LLY

Description

Eli Lilly and Company is a global pharmaceutical firm specializing in the discovery, development, and commercialization of human medicines. The company's core business revolves around a diverse portfolio of treatments addressing significant health challenges, including diabetes, oncology, and immunological disorders. Key products include diabetes medications like Mounjaro and Trulicity, as well as oncology drugs such as Verzenio. Eli Lilly also offers therapies for conditions like rheumatoid arthritis, psoriasis, and migraine, demonstrating a broad therapeutic focus. Strategic collaborations with various partners, including Incyte and Boehringer Ingelheim, support the company's research and development efforts, driving innovation in the pharmaceutical landscape.

LLY|Earnings Snapshot

Earnings Summary

Eli Lilly and Company is a global pharmaceutical firm focused on discovering, developing, and commercializing human medicines across diabetes, oncology, and immunology, with flagship products such as Mounjaro, Trulicity, and Verzenio. Operating in the healthcare drug manufacturers sector, Lilly has leveraged a broad therapeutic portfolio and strategic collaborations to drive innovation. In the last two quarters, Q4 2025 and Q1 2026, Lilly posted revenue of $19.292 billion and $19.799 billion, a year‑over‑year increase of about 3% in Q1 2026 versus Q4 2025, while EPS rose from $7.54 to $8.55, reflecting strong profitability. The company has consistently beat earnings estimates in all eight quarters reported, with EPS exceeding consensus in each period and revenue growth accelerating in the most recent quarters. Historically, Lilly’s YoY growth trajectory has been robust, with revenue increasing by an average of 8% per quarter over the past two years and EPS growth outpacing revenue, underscoring a pattern of margin expansion. Recent news underscores the company’s momentum in the weight‑management and diabetes space, with a 6.4% revenue lift from Mounjaro and Zepbound and UK approval of Foundayo, a GLP‑1 therapy that expands Lilly’s portfolio. The company also announced a 91% revenue jump for Mounjaro and a 46% jump for Zepbound in Q2 2026, reinforcing its core growth engine. Investors should watch the upcoming Q3 2026 guidance for updates on GLP‑1 sales, insulin revenue, and any regulatory approvals, as these factors will clarify the impact of competitive pressure and sustain the current growth narrative. Key will be monitoring the pace of new product approvals and any changes in pricing strategy for its flagship therapies to maintain the current valuation trajectory.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$9.87	-	-
Q2'26	$6.07	$8.38	+38.1%
Q1'26	$6.79	$8.55	+25.9%
Q4'25	$6.74	$7.54	+11.9%
Q3'25	$5.89	$7.02	+19.2%
Q2'25	$5.59	$6.31	+12.9%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$22.2B	-	-
Q2'26	$20.9B	$23.0B	+9.8%
Q1'26	$17.8B	$19.8B	+11.1%
Q4'25	$18.1B	$19.3B	+6.4%
Q3'25	-	$17.6B	-
Q2'25	-	$15.6B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

LLY Stock Snapshot

LLY is currently trading at $1259.77, giving Eli Lilly and Company a market cap of 1153.16B and a P/E ratio of 43.2. Today's range spans $1229.62–$1264.73, with shares opening at $1249.00 and moving up $5.71 (0.5%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 81/100.

Over the past year LLY has traded between $694.23 and $1292.65 - the current price is +81.5% off the 52-week low and -2.5% from the high. 39 analysts cover the stock with a Buy consensus and a mean 12-month target of $1315.04 (range $850.00–$1600.00), implying upside of +4.4%.

The macro environment and LLY's bullish technical reading (86/100, BUY) are aligned right now - a combination that historically has been difficult to fade in mega-cap Healthcare names. Sentiment is running bullish at 81/100, price is $1259.77 (near 52-week highs). (P/E: 43.2) The structural range of $694.23–$1292.65 tells the multi-year story; the current positioning near near 52-week highs tells the short-term one. Both support the same conclusion.

The 52-week range of $694.23–$1292.65 tells the structural story: LLY has demonstrated it can hold ground at the low end and extend meaningfully at the high. At $1259.77 and near 52-week highs, the stock is in territory where momentum-driven capital tends to press positions rather than take profits, especially when news sentiment (81/100, bullish) isn't providing a reason to rotate out.

LLY Competitive Positioning

Eli Lilly and Company (LLY) is tracked alongside these names in Drug Manufacturers - General on DailyIQ.

News Sentiment Analysis

Sentiment gathered from recent headlines

81/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Eli Lilly announced a significant revenue uptick driven by its obesity and diabetes drugs Mounjaro and Zepbound, prompting a raise in full‑year guidance. The company secured UK approval for Foundayo, an oral GLP‑1 pill, broadening its weight‑management and diabetes portfolio. These moves reinforce Lilly’s leadership in GLP‑1 therapies while highlighting ongoing regulatory and payer risks that could temper demand.

What did this article say?

Eli Lilly’s stock rallied after the company announced a new weight‑loss drug that has shown strong efficacy in early trials. The breakthrough positions Lilly as a leader in the rapidly expanding obesity treatment market, potentially capturing a significant share from competitors. Investors are focusing on the drug’s projected sales trajectory and the company’s ability to secure regulatory approvals. The move also highlights Lilly’s broader strategy to diversify beyond its traditional diabetes portfolio.

What did this article say?

The article examines whether Eli Lilly (LLY) might consider a stock split after nearly 30 years since its last split in 1997. It explains that stock splits are typically pursued when share prices become too high for average investors, potentially making the stock more accessible. While no official plan has been announced, the possibility of a split could generate investor excitement and affect trading dynamics.

What did this article say?

Eli Lilly (LLY) reports a sharp earnings surge, underscoring its strong growth trajectory and high profitability. The company’s financial performance outpaces market expectations, reinforcing investor confidence. Technical analysis indicates a bullish breakout, suggesting potential upside momentum. Traders should monitor LLY’s price action for confirmation of the breakout and watch for any earnings guidance that could further influence the stock’s trajectory.

What did this article say?

The article reports that shareholders are pressuring Capricor while Lilly is deepening its vaccine strategy. It suggests that Lilly may be positioning itself for growth in the vaccine sector. The piece hints at potential strategic shifts and investor expectations.

What did this article say?

Eli Lilly (LLY) has seen a surge in investor interest following the UK Medicines and Healthcare products Regulatory Agency’s approval of Foundayo, a once‑daily oral GLP‑1 therapy for weight management and type 2 diabetes. The approval has bolstered the company’s GLP‑1 narrative, contributing to an 11.63% 30‑day share return and an 18.51% year‑to‑date gain. Analysts note that the approval aligns with recent pipeline deals, reinforcing LLY’s valuation upside and supporting a bullish stance for the stock. The company’s share price, hovering near $1,280, now sits above the fair‑value estimate of $1,477, indicating potential upside if the market continues to price in the GLP‑1 momentum. Investors should monitor LLY’s earnings guidance for Q4 and any additional regulatory approvals in the U.S. market.

What did this article say?

Novo Nordisk has introduced Awiqli, a once‑weekly basal insulin, to diversify its diabetes portfolio amid slowing growth of its GLP‑1 products. The launch directly challenges Eli Lilly’s (LLY) insulin offerings, potentially reshaping market share dynamics. Adoption will hinge on physician acceptance and patient preference for weekly dosing. The move signals a strategic pivot that could alter competitive positioning in the U.S. diabetes market.

What did this article say?

The Tema Oncology ETF (CANC) recently reached a new 52‑week high, with Eli Lilly & Co representing 5.01% of its holdings. The fund’s surge reflects broader momentum in oncology, driven by recent positive trial results from peers such as Merck and Moderna. For traders, the ETF’s performance may signal continued upside in the oncology space, potentially benefiting Lilly’s oncology portfolio. Key catalysts include upcoming quarterly earnings and any new approvals for Lilly’s oncology products.

What did this article say?

Eli Lilly’s weight‑loss program continues to generate strong market interest, with Phase 3 trials showing an average 28.3% weight reduction. The company’s valuation has risen to roughly $1.1 trillion, and management recently lifted its 2026 revenue guidance. Analysts view the upcoming launch of retatrutide as a potential catalyst for sustaining the premium valuation. Investors should monitor the regulatory approval timeline and any updates on the Phase 3 TRIUMPH‑1 study results.

What did this article say?

OPKO Health has raised $125 million through senior secured notes backed by royalties from its mazdutide license with Eli Lilly. The financing extends OPKO’s royalty‑backed funding model while preserving long‑term participation in royalty growth in China. The deal provides non‑dilutive capital that can support clinical development and operating needs, though it commits a portion of future royalty economics to the lender. The transaction underscores Lilly’s continued involvement in the commercial progress of mazdutide in China and highlights the strategic partnership between the two companies.